GT Medical Technologies Announces $16 Million Financing to Expand Availability of Targeted Therapy for Patients with Recurrent Brain Tumors
GT Medical Technologies, Inc., a company dedicated to improving the lives of patients with brain tumors, today announced it has raised $16 million in a Series B financing led by MVM Partners with participation from existing investors MedTech Venture Partners and BlueStone Venture Partners.
Read More →
GT Medical Wins Expanded Indication for GammaTile Therapy
The U.S. Food and Drug Administration (FDA) has cleared an expanded indication for GammaTile Therapy from GT Medical Technologies Inc. Patients with newly diagnosed malignant brain tumors are now eligible to receive the FDA-cleared surgically targeted radiation therapy (STaRT). “We are pleased... Read More →
GT Medical Technologies Announces $10 Million Financing to Support Launch of Targeted Therapy for Patients with Recurrent Brain Tumors
TEMPE, Ariz.–(BUSINESS WIRE)–GT Medical Technologies, Inc., a company dedicated to improving the lives of patients with brain tumors, today announced that it has raised $10 million in a Series A financing led by MedTech Venture Partners with participation from BlueStone... Read More →